ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

Stephanie A. Yazinski; Valentine Comaills; Rémi Buisson; Marie Michelle Genois; Hai Dang Nguyen; Chu Kwen Ho; Tanya Todorova Kwan; Robert Morris; Sam Lauffer; André Nussenzweig; Sridhar Ramaswamy; Cyril H. Benes; Daniel A. Haber; Shyamala Maheswaran; Michael J. Birrer; Lee Zou

doi:10.1101/gad.290957.116

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

Stephanie A. Yazinski, Valentine Comaills, Rémi Buisson, Marie Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig, Sridhar Ramaswamy, Cyril H. Benes, Daniel A. Haber, Shyamala Maheswaran, Michael J. Birrer, Lee Zou

Research output: Contribution to journal › Article › peer-review

318 Scopus citations

Abstract

Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.

Original language	English (US)
Pages (from-to)	318-332
Number of pages	15
Journal	Genes and Development
Volume	31
Issue number	3
DOIs	https://doi.org/10.1101/gad.290957.116
State	Published - Feb 1 2017
Externally published	Yes

Bibliographical note

Funding Information:
We thank S. Cantor, J. Chen, D. Durocher, N. Dyson, L. Ellisen, S. Orsulic, and B. Xia for reagents and discussions. This work was supported by grants from the National Institutes of Health (GM076388 and CA197779 to L.Z., and CA129933 to D.A.H.), National Cancer Institute Federal Share of Program Income (to L.Z.), Jim and Ann Orr MGH Research Scholar Award (to L.Z.), Susan Komen for the Cure (KG09042 to S.M.), and the Wellcome Trust (102696 to C.H.B.). The Flow Cytometry Core is supported by National Institutes of Health instrumentation grant 1S10RR023440-01A1. S.A.Y. was supported by a fellowship from the Department of Defense (W81XWH-13-1-0027). V.C. and R.B. have received support from the Philippe Foundation. M.-M.G. is a fellow of Fonds de recherche du Qu?bec-Sant?. H. D. N. was a Medical Discovery Post-doctoral Fellow. R.B. was a Marsha Rivkin Scholar. L.Z. is the James and Patricia Poitras Endowed Chair in Cancer Research.

Publisher Copyright:
© 2017 Yazinski et al.

Keywords

ATR
BRCA-deficient cancer
PARP inhibitor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1101/gad.290957.116

Find It

Find It at U of M Libraries

Cite this

Yazinski, S. A., Comaills, V., Buisson, R., Genois, M. M., Nguyen, H. D., Ho, C. K., Kwan, T. T., Morris, R., Lauffer, S., Nussenzweig, A., Ramaswamy, S., Benes, C. H., Haber, D. A., Maheswaran, S., Birrer, M. J., & Zou, L. (2017). ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes and Development, 31(3), 318-332. https://doi.org/10.1101/gad.290957.116

Yazinski, SA, Comaills, V, Buisson, R, Genois, MM, Nguyen, HD, Ho, CK, Kwan, TT, Morris, R, Lauffer, S, Nussenzweig, A, Ramaswamy, S, Benes, CH, Haber, DA, Maheswaran, S, Birrer, MJ & Zou, L 2017, 'ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells', Genes and Development, vol. 31, no. 3, pp. 318-332. https://doi.org/10.1101/gad.290957.116

@article{01c15f0c315a4801a36de6625565d4c7,

title = "ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells",

abstract = "Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.",

keywords = "ATR, BRCA-deficient cancer, PARP inhibitor",

author = "Yazinski, {Stephanie A.} and Valentine Comaills and R{\'e}mi Buisson and Genois, {Marie Michelle} and Nguyen, {Hai Dang} and Ho, {Chu Kwen} and Kwan, {Tanya Todorova} and Robert Morris and Sam Lauffer and Andr{\'e} Nussenzweig and Sridhar Ramaswamy and Benes, {Cyril H.} and Haber, {Daniel A.} and Shyamala Maheswaran and Birrer, {Michael J.} and Lee Zou",

note = "Funding Information: We thank S. Cantor, J. Chen, D. Durocher, N. Dyson, L. Ellisen, S. Orsulic, and B. Xia for reagents and discussions. This work was supported by grants from the National Institutes of Health (GM076388 and CA197779 to L.Z., and CA129933 to D.A.H.), National Cancer Institute Federal Share of Program Income (to L.Z.), Jim and Ann Orr MGH Research Scholar Award (to L.Z.), Susan Komen for the Cure (KG09042 to S.M.), and the Wellcome Trust (102696 to C.H.B.). The Flow Cytometry Core is supported by National Institutes of Health instrumentation grant 1S10RR023440-01A1. S.A.Y. was supported by a fellowship from the Department of Defense (W81XWH-13-1-0027). V.C. and R.B. have received support from the Philippe Foundation. M.-M.G. is a fellow of Fonds de recherche du Qu?bec-Sant?. H. D. N. was a Medical Discovery Post-doctoral Fellow. R.B. was a Marsha Rivkin Scholar. L.Z. is the James and Patricia Poitras Endowed Chair in Cancer Research. Publisher Copyright: {\textcopyright} 2017 Yazinski et al.",

year = "2017",

month = feb,

day = "1",

doi = "10.1101/gad.290957.116",

language = "English (US)",

volume = "31",

pages = "318--332",

journal = "Genes and Development",

issn = "0890-9369",

publisher = "Cold Spring Harbor Laboratory Press",

number = "3",

}

TY - JOUR

T1 - ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

AU - Yazinski, Stephanie A.

AU - Comaills, Valentine

AU - Buisson, Rémi

AU - Genois, Marie Michelle

AU - Nguyen, Hai Dang

AU - Ho, Chu Kwen

AU - Kwan, Tanya Todorova

AU - Morris, Robert

AU - Lauffer, Sam

AU - Nussenzweig, André

AU - Ramaswamy, Sridhar

AU - Benes, Cyril H.

AU - Haber, Daniel A.

AU - Maheswaran, Shyamala

AU - Birrer, Michael J.

AU - Zou, Lee

N1 - Funding Information: We thank S. Cantor, J. Chen, D. Durocher, N. Dyson, L. Ellisen, S. Orsulic, and B. Xia for reagents and discussions. This work was supported by grants from the National Institutes of Health (GM076388 and CA197779 to L.Z., and CA129933 to D.A.H.), National Cancer Institute Federal Share of Program Income (to L.Z.), Jim and Ann Orr MGH Research Scholar Award (to L.Z.), Susan Komen for the Cure (KG09042 to S.M.), and the Wellcome Trust (102696 to C.H.B.). The Flow Cytometry Core is supported by National Institutes of Health instrumentation grant 1S10RR023440-01A1. S.A.Y. was supported by a fellowship from the Department of Defense (W81XWH-13-1-0027). V.C. and R.B. have received support from the Philippe Foundation. M.-M.G. is a fellow of Fonds de recherche du Qu?bec-Sant?. H. D. N. was a Medical Discovery Post-doctoral Fellow. R.B. was a Marsha Rivkin Scholar. L.Z. is the James and Patricia Poitras Endowed Chair in Cancer Research. Publisher Copyright: © 2017 Yazinski et al.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.

AB - Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) selectively kill BRCA1/2-deficient cells, but their efficacy in BRCA-deficient patients is limited by drug resistance. Here, we used derived cell lines and cells from patients to investigate how to overcome PARPi resistance. We found that the functions of BRCA1 in homologous recombination (HR) and replication fork protection are sequentially bypassed during the acquisition of PARPi resistance. Despite the lack of BRCA1, PARPi-resistant cells regain RAD51 loading to DNA double-stranded breaks (DSBs) and stalled replication forks, enabling two distinct mechanisms of PARPi resistance. Compared with BRCA1-proficient cells, PARPi-resistant BRCA1-deficient cells are increasingly dependent on ATR for survival. ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms. In tumor cells derived from patients, ATRis also overcome the bypass of BRCA1/2 in fork protection. Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-deficient cancers.

KW - ATR

KW - BRCA-deficient cancer

KW - PARP inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85014830795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014830795&partnerID=8YFLogxK

U2 - 10.1101/gad.290957.116

DO - 10.1101/gad.290957.116

M3 - Article

C2 - 28242626

AN - SCOPUS:85014830795

SN - 0890-9369

VL - 31

SP - 318

EP - 332

JO - Genes and Development

JF - Genes and Development

IS - 3

ER -

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this